Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors.
Degorce, S.L., Aagaard, A., Anjum, R., Cumming, I.A., Diene, C.R., Fallan, C., Johnson, T., Leuchowius, K.J., Orton, A.L., Pearson, S., Robb, G.R., Rosen, A., Scarfe, G.B., Scott, J.S., Smith, J.M., Steward, O.R., Terstiege, I., Tucker, M.J., Turner, P., Wilkinson, S.D., Wrigley, G.L., Xue, Y.(2020) Bioorg Med Chem 28: 115815-115815
- PubMed: 33091850 
- DOI: 10.1016/j.bmc.2020.115815
- Primary Citation of Related Structures:  
6THW, 6THX, 6THZ, 6TI8, 6TIA - PubMed Abstract: 
In this article, we report our efforts towards improving in vitro human clearance in a series of 5-azaquinazolines through a series of C4 truncations and C2 expansions. Extensive DMPK studies enabled us to tackle high Aldehyde Oxidase (AO) metabolism and unexpected discrepancies in human hepatocyte and liver microsomal intrinsic clearance ...